UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2025
Commission File No. 001-38773
CHINA SXT PHARMACEUTICALS, INC.
(Translation of registrant’s name into English)
178 Taidong Rd North, Taizhou
Jiangsu, China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☒ Form
40-F ☐
Submission of Matters to a Vote of Security Holders.
On
July 28, 2025, China SXT Pharmaceuticals, Inc. (the “Company”) held a special meeting of shareholders (the “Meeting”)
at 9 a.m., EST, at 178 Taidong Road North Taizhou, Jiangsu, People’s Republic of China. Each ordinary share is entitled to one.
Holders
of a total of 39,648,847 ordinary shares, out of a total of 116,027,758 ordinary shares issued and outstanding and entitled to vote at
the Meeting have voted. Therefore, a quorum of more than one-third of all votes attaching to the total issued voting shares in the Company
at the Meeting as of the record date of July 9, 2025 was reached. The final voting results for each matter submitted to a vote of shareholders
at the Meeting are as follows:
| 1. | Creation of a new class of Class B Ordinary Shares and re-designation
of the existing issued and unissued Ordinary Shares as Class A Ordinary Shares, and Amendment to the Memorandum and Articles of Association. |
It was approved to change the Company’s
authorized share capital to comprise of a dual class of shares through (i) creating a new class of shares comprising unlimited Class B
Ordinary Shares (the “Creation of New Class”) which entitle the holder to fifty (50) votes per Class B Ordinary
Share on any resolution of shareholders; (ii) re-designating an aggregate of then issued 532 Ordinary Shares held by Feng Zhou Management
Limited into 532 Class B Ordinary Shares (the “Re-designation of Class B Shares”); (iii) re-designating the remaining
then issued 116,027,226 Ordinary Shares as 116,027,226 Class A Ordinary Shares with no par value each (the “Re-designation
of Class A Shares”); (iv) other consequential updates including the rights of Class B Ordinary Shares, in the form of the amended
and restated memorandum and articles of association, a copy of which is attached as Exhibit 3.1 (the “New Amended MAA”);
and (v) adopting the New Amended MAA as the memorandum and articles of association of the Company, to the exclusion of the existing amended
and restated memorandum and articles of association, where the New Amended MAA will become effective upon filing with the Companies Registry
of the British Virgin Islands by the Company.
| For |
|
Against |
|
Abstain |
| 39,642,273 |
|
6,445 |
|
129 |
The foregoing description of the amendments is
qualified in its entirety by reference to the full text of the New Amended MAA, a copy of which is attached as Exhibit 3.1 hereto
and is incorporated by reference herein.
Exhibits
| Exhibit No. |
|
Exhibit |
| 3.1 |
|
Amended and Restated Articles of Association adopted on July 28, 2025. |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: July 29, 2025
| |
China SXT Pharmaceuticals, Inc. |
| |
|
|
| |
By: |
/s/ Feng Zhou |
| |
Name: |
Feng Zhou |
| |
Title: |
Co-Chief Executive Officer |
| |
By: |
/s/ Simon Lim Sze Beng |
| |
Name: |
Simon Lim Sze Beng |
| |
Title: |
Co-Chief Executive Officer |
3
